Deproxy Suppositories Rectal #10

Name - DEPROX Suppository Rectal #10 DEPROX 500 is included in the 2022 European Association of Urology recommended protocol for the treatment of the following conditions: Acute and chronic prostatitis Benign prostatic hyperplasia Chronic pelvic pain syndrome Lower urinary tract symptoms (LUTS) Preoperative and postoperative conditions of the prostate gland DEPROX 500 suppositories have: Antiproliferative properties due to G63 (Graminex) suppressive action on NF-κB phosphorylation (strong mitogenic inhibitory property) Anti-inflammatory action manifested by suppression of inflammatory cytokine synthesis (IL-6, IL-8, IL-1b, TNF), as well as cyclooxygenase and 5-lipoxygenase synthesis Analgesic action achieved by affecting transient receptor potentials Treatment with DEPROX suppositories leads to regression of interstitial edema and fibrosis, which eliminates the clinical symptomatology associated with the disease DEPROX suppositories aid in the regeneration of the rectal mucosa, forming a protective barrier that prevents the spread of microorganisms Analgesic ability at the ano-rectal level is related to the effect on transient receptor potentials DEPROX has: Over 100 clinical studies Accredited clinical studies directly on DEPROX 500 In the first year of the drug's release, DEPROX 500 was included in a placebo-controlled, randomized, double-blind clinical study involving 3,347 patients who successfully completed treatment Indications for DEPROX rectal suppositories: Acute and chronic prostatitis (bacterial and non-bacterial etiology) Benign prostatic hyperplasia Chronic pelvic pain syndrome Lower urinary tract symptoms (LUTS) Preoperative and postoperative conditions of the prostate gland Dosage: 1 rectal suppository, in the evening before sleep